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ORIGINAL ARTICLE
Additional molecular testing of saliva specimens
improves the detection of respiratory viruses
Kelvin KW To1,2,3,4,5, Lu Lu4, Cyril CY Yip5, Rosana WS Poon5, Ami MY Fung5, Andrew Cheng5,
Daniel HK Lui6, Deborah TY Ho4, Ivan FN Hung1,2,7, Kwok-Hung Chan1,2,3,4 and Kwok-Yung Yuen1,2,3,4,5
Emerging infectious diseases in humans are often caused by respiratory viruses such as pandemic or avian inﬂuenza viruses and
novel coronaviruses. Microbiological testing for respiratory viruses is important for patient management, infection control and
epidemiological studies. Nasopharyngeal specimens are frequently tested, but their sensitivity is suboptimal. This study
evaluated the incremental beneﬁt of testing respiratory viruses in expectorated saliva using molecular assays. A total of 258
hospitalized adult patients with suspected respiratory infections were included. Their expectorated saliva was collected without
the use of any special devices. In the ﬁrst cohort of 159 patients whose nasopharyngeal aspirates (NPAs) tested positive for
respiratory viruses during routine testing, the viral load was measured using quantitative reverse transcription PCR. Seventeen
percent of the patients (27/159) had higher viral loads in the saliva than in the NPA. The second cohort consisted of 99
patients whose NPAs tested negative for respiratory viruses using a direct immunoﬂuorescence assay. Their NPA and saliva
specimens were additionally tested using multiplex PCR. In these patients, the concordance rate by multiplex PCR between NPA
and saliva was 83.8%. Multiplex PCR detected viruses in saliva samples from 16 patients, of which nine (56.3%) had at least
one virus that was not detected in the NPA. Decisions on antiviral or isolation precautions would be affected by salivary testing
in six patients. Although NPAs have high viral loads and remain the specimen of choice for most patients with respiratory virus
infections, supplementary molecular testing of saliva can improve the clinical management of these patients.
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INTRODUCTION
Viruses play important roles in respiratory tract infections.1–4
Recently, several novel respiratory viruses have emerged, including
the 2009 pandemic inﬂuenza virus A(H1N1)pdm09,5 the avian
inﬂuenza viruses A(H7N9) and A(H5N6),6–8 and the Middle East
Respiratory Syndrome (MERS) coronavirus.9 The novel avian inﬂu-
enza viruses and the MERS coronavirus are associated with high
mortality rates of over 30%.
Prompt and accurate detection of respiratory viruses is important
for guiding antiviral treatment.10 For inﬂuenza virus infection, earlier
administration of neuraminidase inhibitors is associated with faster
resolution of symptoms in randomized clinical trials and improved
survival in retrospective studies.11,12 Hyperimmune intravenous
immunoglobulin confers survival beneﬁt for severe inﬂuenza only if
administered within 5 days after symptom onset.13 Antibiotic usage
can be reduced if a respiratory virus is detected without evidence of
bacterial infection.14 Early detection is also important for infection
control and public health measures.
Nasopharyngeal aspirate (NPA), nasopharyngeal swabs (NPS)
(including ﬂocked swabs), and nasal or throat swabs/washes are the
recommended upper respiratory tract specimen types for diagnostic
testing of respiratory viruses.15,16 Nasopharyngeal specimens are
usually considered to have the highest detection rate for respiratory
viruses. Nasopharyngeal specimens are often used as the only speci-
men type in routine clinical practice and in many surveillance studies
for the detection of respiratory viruses.17 However, in studies that have
tested multiple specimen types, nasopharyngeal specimens have been
found to be negative in some patients with respiratory virus
infections.18–22 Sputum or other lower respiratory tract specimens
may contain a higher viral load for some patients, which will improve
the detection of viruses. Jeong et al showed that nasopharyngeal swabs
were negative in 25% of adult patients with sputum positive for
respiratory viruses.19 However, many patients do not have sputum
production or cannot expectorate good quality sputum. Additionally,
the collection of tracheal or bronchial specimens involves invasive
procedures that are associated with signiﬁcant discomfort and risk to
the patient and pose a risk to healthcare workers.23,24
Saliva can be easily provided by patients without any invasive
procedures. However, saliva is rarely used for the detection of
respiratory viruses, because it is generally considered to have inferior
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sensitivity compared with other respiratory tract specimens. MUC5B,
salivary gp-340, histatins, and human neutrophil defensins in saliva
have been shown to neutralize inﬂuenza A virus.25 Moreover, saliva is
not a suitable specimen type for direct immunoﬂuorescence assay
(DFA) because it does not contain a sufﬁcient amount of infected
respiratory epithelial cells. Recently, there has been renewed interest in
using saliva for the detection of respiratory viruses with molecular
assays.18,26–29 Some of these studies showed that the detection rate of
respiratory viruses was actually higher for saliva than for nasophar-
yngeal specimens.18 However, these studies were conducted either in
children28 or among adult patients with mild symptoms who did not
require hospitalization.18,27 Some studies only evaluated the detection
of inﬂuenza virus.26,29 Furthermore, many of these studies used special
collection devices that are not usually available in most hospitals. The
utility of saliva for the detection of respiratory viruses among
hospitalized adult patients has not been comprehensively studied.
The current study sought to evaluate the beneﬁt of testing
expectorated saliva in addition to NPA among adult patients
hospitalized for a suspected respiratory tract infection. The aim of
the ﬁrst part of the study was to assess the difference in the viral load
between NPA and saliva using quantitative PCR with reverse
transcription (RT-PCR). The aim of the second part of the study
was to evaluate the incremental beneﬁt of testing saliva in addition to
NPA using a commercially available molecular assay. As the current
study was designed to enable the easy application of our saliva
specimen collection method to any clinical setting, we asked the study
participants to provide saliva specimens by simple expectoration into a
sterile bottle without using any special collection devices.
MATERIALS AND METHODS
Study design and participants
This study was a 1-year prospective study conducted between 1 March
2015, and 29 February 2016, in Queen Mary Hospital, which is a
teaching hospital in Hong Kong with 1600 beds. This study was
approved by the Institutional Review Board of the University of Hong
Kong/Hospital Authority Hong Kong West Cluster. Written informed
consent was obtained from all study participants. Patients were eligible
for recruitment if they were hospitalized adult patients aged 18 years
or above with a suspected respiratory tract infection and had NPA
samples obtained for respiratory virus testing. Saliva specimens were
collected from the enrolled patients when the result of the routine
clinical testing for respiratory viruses in the clinical microbiology
laboratory of Queen Mary Hospital was known. Therefore, a patient’s
saliva specimen was always collected after the NPA specimen. Patients
were excluded from the study if they were discharged from the
hospital before enrollment, were unable to provide a saliva specimen,
or refused or were unable to provide written informed consent.
The ﬁrst part of the study consisted of patients whose NPA samples
tested positive for respiratory viruses by DFA or the inﬂuenza A virus
M gene by real-time RT-PCR during routine respiratory virus testing
in our clinical microbiology laboratory (Figure 1). The viral load was
determined in both the NPA and the saliva samples using quantitative
RT-PCR (qRT-PCR). During the ﬁrst phase (1 March to 15 June
2015), only patients who tested positive for inﬂuenza A virus were
included. During the second phase (16 June 2015 to 29 February
2016), patients who tested positive for any respiratory viruses were
included.
The second part of the study consisted of patients whose NPA
specimens either tested negative for respiratory viruses by DFA or had
insufﬁcient nasopharyngeal columnar epithelial cells (NPCs) in the
NPA sample for DFA during routine clinical testing (Figure 1).
Insufﬁcient NPCs was deﬁned as o20 NPCs in the entire well.
Multiplex PCR was used to test for respiratory viruses in both the NPA
and the saliva samples.
Data collection
Patient data concerning demographics, underlying diseases, clinical
ﬁndings and radiological changes were recorded in a predesigned
database. The Charlson comorbidity score was calculated.30 Pneumo-
nia was deﬁned by radiological evidence of new or increased
pulmonary inﬁltrate in a chest radiograph and at least one of the
following symptoms (cough with or without sputum production,
dyspnea, tachypnea, or pleuritic chest pain) plus one auscultatory
ﬁnding or one sign of infection (core body temperature 438 °C,
shivers, leukocyte count 410 000 cells/μL or o4000 cells/μL) as
described previously.31
Routine respiratory virus testing in the clinical microbiology
laboratory
NPA samples were collected in viral transport medium (VTM) as
described previously.32 Routine testing for respiratory viruses was
performed using antigen detection by DFA (D3 Ultra 8 DFA
Respiratory Virus Screening and Identiﬁcation Kit, Diagnostic Hybrids,
Inc., Quidel, San Diego, CA, USA), which included inﬂuenza A virus,
and inﬂuenza B virus, parainﬂuenza viruses 1–3, respiratory syncytial
virus (RSV), human metapneumovirus (hMPV) and adenovirus. From
1 March to 8 April 2015 (during the peak inﬂuenza A virus season in
Hong Kong), real-time RT-PCR for the inﬂuenza A virus M gene was
performed for patients admitted to the general medical ward as
described previously.33 During this period, DFA was not performed
if the NPA samples tested positive for inﬂuenza A virus using RT-PCR.
Saliva specimen collection
Patients were instructed to expectorate saliva into a sterile container
and 2 mL of VTM was added to the container in the microbiology
laboratory. The volume of saliva ranged between ~ 0.5 and 1 mL.
Figure 1 Study design. nasopharyngeal aspirate, NPA; quantitative PCR
with reverse transcription, qRT-PCR. aRoutine clinical testing was performed
using antigen detection by the DFA, which included the inﬂuenza A and B
viruses, parainﬂuenza virus types 1–3, respiratory syncytial virus, human
metapneumovirus and adenovirus. From 1 March to 8 April 2015 (during
the peak inﬂuenza A virus season), monoplex real-time RT-PCR for the
inﬂuenza A M gene was performed for patients admitted to the general
medical ward. bPatients whose NPA specimens either tested negative for
respiratory viruses by DFA or had insufﬁcient NPCs for DFA during routine
clinical testing. Insufﬁcient NPCs is deﬁned as o20 NPCs in the
entire well.
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Quantitative RT-PCR for respiratory viruses
Total nucleic acid (TNA) extraction was performed using the easy-
MAG instrument (bioMerieux, Boxtel, Netherlands) as described
previously.34,35 NPA or saliva specimens in VTM (250 μL) were
mixed with lysing buffer. After extraction, the nucleic acids were
recovered using 55 μL of elution buffer.
qRT-PCR for inﬂuenza A virus detection was carried out using
Superscript III Platinum One-Step RT-PCR reagents (Invitrogen,
Carlsbad, CA, USA) as described previously with modiﬁcations.13,33,34
The reagent mixture (25 μL) contained the 1×Reaction Mix, Super-
script III RT/Platinum Taq Mix, ROX reagent, 0.8 μM of the forward
and reverse primers, 0.2 μM of the probe and 5 μL of TNA as the
template. The thermal cycling conditions were 30 min at 50 °C for
reverse transcription, 2 min at 95 °C for RT inactivation/initial
denaturation, and 50 cycles of 15 s at 95 °C and 30 s at 55 °C. All
reactions were performed using the StepOnePlus Real-Time PCR
System (Applied Biosystems, Foster City, CA, USA).
The qRT-PCR for the detection of inﬂuenza B virus, parainﬂuenza
viruses 1–3, hMPV and respiratory syncytial virus was carried out
using AgPath-ID One-Step RT-PCR reagents (Applied Biosystems).
The reagent mixture (25 μL) contained 1×RT-PCR Buffer, 1 ×RT-
PCR Enzyme Mix, 0.4 μM of the forward and reverse primers,
0.12 μM of the probe and 5 μL of TNA as the template. The thermal
cycling conditions were 10 min at 45 °C for reverse transcrip-
tion, 10 min at 95 °C for RT inactivation/initial denaturation, and
50 cycles of 15 s at 95 °C and 45 s at 55 °C. All reactions were
performed using the LightCycler 96 Real-Time PCR System (Roche,
Basel, Switzerland). The primer and probe sequences are shown in
Table 1.
Multiplex PCR panel for respiratory viruses
The multiplex PCR for respiratory viruses was performed using the
NxTAG Respiratory Pathogen Panel (IVD) (Luminex, Austin, TX,
USA) according to the manufacturer’s instructions. Respiratory viruses
detected by this assay included inﬂuenza A virus, inﬂuenza B virus,
RSV A and B, enterovirus/rhinovirus (EV/RV), parainﬂuenza viruses
1–4, hMPV, adenovirus, coronaviruses HKU1, NL63, 229E and OC43,
and human bocavirus. Extracted TNA was added to pre-plated
Lyophilized Bead Reagents. The reaction was ampliﬁed via RT-PCR,
and the reaction product underwent bead hybridization within the
sealed reaction well. The hybridized and tagged beads were sorted and
read on the MAGPIX instrument, and the signals were analyzed using
the NxTAG Respiratory Pathogen Panel Assay File for the SYNCT
Software (Luminex, Austin, TX, USA).
Statistical analysis
The Mann-Whitney U-test and Fisher’s exact test were used for
comparisons of continuous and categorical variables, respectively. The
Wilcoxon matched-pairs signed rank test was used for the comparison
between the NPA and saliva viral loads. Correlations between the viral
loads in the NPA and saliva specimens were determined using
Spearman’s correlation coefﬁcient. McNemar’s test was used to
compare the positivity rates between the NPA and the saliva speci-
mens. Log-transformed data were used for statistical calculations of
the viral load. The statistical analysis was performed using SPSS 21.0
(IBM Corp., Armonk, NY, USA) or GraphPad Prism 6.0 (GraphPad
Software, La Jolla, CA, USA).
RESULTS
First cohort: comparison of the viral loads between the NPA and
the saliva samples
The ﬁrst cohort consisted of 159 patients with known respiratory virus
infection (Table 2 and Supplementary Table S1). The median age was
69 years, with a range from 20 to 98 years. The median Charlson
comorbidity score was 1. Forty (25.2%) patients had pneumonia, two
patients (1.3%) required admission to the intensive care unit, and two
patients (1.3%) died. Most of the saliva specimens were collected
o2 days after the collection of the NPA sample (91.8%, 146/159).
Among this ﬁrst cohort of patients with a respiratory virus detected in
the NPA sample during routine clinical testing, the qRT-PCR for the
same virus was positive in the NPA specimens of all patients and in the
saliva specimens of 91.8% (146/159) of the patients (Table 2). Among
the 99 patients who tested positive for inﬂuenza A virus, the NPA
specimens of 12 patients were tested by inﬂuenza A virus M gene RT-
PCR only during the routine clinical service. The saliva sample was
positive by qRT-PCR in 11 out of these 12 patients (91.7%). Although
the median viral load was signiﬁcantly greater in the NPA than in the
saliva samples (7.23 vs 5.30 log10 copies per mL, Po0.0001), 17.0%
(27/159) of the patients had a higher viral load in the saliva than in
their NPA sample (Figure 2A). No signiﬁcant correlation was found
between the viral load in the NPA and that in the saliva (P= 0.071).
Among the patients with inﬂuenza A or inﬂuenza B virus infection, no
signiﬁcant difference was found in the median salivary viral load
Table 1 Primers and probes used in the quantitative reverse
transcription PCR
Virus Primer/probe sequence (5′-3′)
Inﬂuenza A virus Forward GACCRATCCTGTCACCTCTGAC
Reverse AGGGCATTYTGGACAAAKCGTCTA
Probe FAM- TGCAGTCCTCGCTCACTGGGCACG -BHQ1
Inﬂuenza B virus Forward ACAATTGCCTACYTGCTTTCA
Reverse TCTTTCCCACCRAACCAAC
Probe HEX- AGAAGATGGAGAARGCAAAGCAGAACTAGC
-IABkFQ
Human
metapneumovirus
Forward CATAYAARCATGCTATATTRAAAGAGTCTC
Reverse CCTATYTCWGCAGCATATTTGTAATCAG
Probe FAM- CAACHGCAGTRACACCYTCATCATTRCA
-IABkFQ
Respiratory syncytial
virus
Forward CTTAGCAAAGTCAAGTTRAATGATACA
Reverse TGCACATCATAATTRGGAGTGTC
Probe HEX- ACYATYCAACGKAGYACAGGAGA -IABkFQ
Parainﬂuenza virus
type 1
Forward GGAGGAGCAATTATACCTGGTCA
Reverse TGTATCCARTGAGTGGGCTA
Probe LC610- ATTAGGCCCGAGTGTRACRGATGATGC
-BBQ
Parainﬂuenza virus
type 2
Forward TATGCYATGGTGGGAGACATT
Reverse GCCATCTTGTTCCAAGTCCAT
Probe FAM- CCTCCCATTCCGCTGTGTTCAATRTACTT
-IABkFQ
Parainﬂuenza virus
type 3
Forward AGCTATYACTAGYATCTCAGGGT
Reverse CCCAATCTGATCCACTGTGT
Probe HEX- TCAGACAAGATGGAACAGTGCAGGCA
-IABkFQ
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between the patients with saliva collected before and those with saliva
collected after oseltamivir treatment (5.43 vs 4.90 log10 copies per mL,
P= 0.476; Figure 2B). No signiﬁcant difference in the median viral
load was detected in the saliva specimens between patients with
pneumonia and those without pneumonia (5.12 vs 5.13 log10 copies
per mL, P= 0.218; Figure 2C).
Second cohort: multiplex PCR testing of the NPA and the saliva
samples
In the second part of the study, multiplex PCR using the Luminex
NxTAG Respiratory Pathogen Panel was performed on the saliva and
NPA specimens of 99 patients whose NPA specimens tested negative
by DFA (n= 80) or were considered unsuitable for DFA due to
insufﬁcient NPCs (n= 19) during routine clinical testing (Supple-
mentary Table S1). Twenty-ﬁve patients (25.3%) had pneumonia. At
least one respiratory virus was detected in 22.2% (22/99) of the
patients, with one virus detected in 20.2% (20/99) of the patients, two
viruses detected in 1.0% (1/99) of the patients, and three viruses
detected in 1.0% (1/99) of the patients. Hence, a total of 25 viruses
were detected (Tables 3 and 4). At least one respiratory virus was
detected in 14.1% (14/99) and 16.2% (16/99) of the NPA and the
saliva samples, respectively (Table 3; P= 0.789). Eighty-three patients
(83.8%) showed complete concordance, with the multiplex PCR on
the NPA and the saliva samples showing the presence or absence of
exactly the same respiratory viruses (κ coefﬁcient of 0.335 (95%
conﬁdence interval: 0.081–0.589)).
Respiratory viruses were detected in the saliva specimens of 8
(9.4%) of the 85 patients whose NPA specimens tested negative by
NxTAG Respiratory Pathogen Panel, including three patients with
inﬂuenza A virus, two patients with hMPV, two patients with EV/RV
and one patient with coronavirus OC43 (Table 5). For the 14 patients
whose NPA specimens tested positive by the NxTAG Respiratory
Pathogen Panel, one patient had an additional virus species detected in
her saliva (Patient 4 in Table 5). Potential changes in the antiviral
treatment or infection control practice would be possible for six of the
nine patients with additional viruses detected in their saliva. The three
patients with inﬂuenza A virus infection could have been given
neuraminidase inhibitor, whereas the three patients with hMPV
should have been placed under contact precaution.36
Table 2 Detection of viruses using quantitative real-time reverse transcription PCR in the ﬁrst cohort of patients
Virus Number of patients with the virus detected in the NPA during routine
clinical testinga
Saliva-positive, number
(%)
Higher viral load in saliva than in NPA,
number (%)
Inﬂuenza A virus 99b,c 95 (96.0) 17 (17.2)
Respiratory syncytial virus 18 15 (83.3) 1 (5.6)
Human metapneumovirus 14 11 (78.6) 2 (14.3)
Inﬂuenza B virus 12 10 (83.3) 3 (25)
Parainﬂuenza virus type 3 8 8 (100) 2 (25.0)
Parainﬂuenza virus type 1 5 4 (80) 1 (20.0)
Parainﬂuenza virus type 2 3 3 (100) 1 (33.3)
All viruses 159 146 (91.8) 27 (17.0)d
Abbreviations: direct immunoﬂuorescence, DFA; nasopharyngeal aspirate, NPA; PCR with reverse transcription, RT-PCR.
aRoutine clinical testing was performed using antigen detection by DFA, which included inﬂuenza A and B viruses, parainﬂuenza virus types 1–3, respiratory syncytial virus, human metapneumovirus
and adenovirus. From 1 March to 8 April 2015 (during the peak season of inﬂuenza A virus), monoplex real-time RT-PCR for inﬂuenza A M gene was performed for patients admitted to the general
medical ward. Among patients recruited in this study, there were no patients with adenovirus detected in their NPA during routine clinical testing.
bEighty-four patients were infected with H3 subtype, while 15 patients were infected with H1 subtype.
cEighty-seven patients (87.9%) were tested positive for inﬂuenza A virus using antigen detection by direct immunoﬂuorescence. Twelve patients (12.1%; all infected with H3 subtype) admitted to
the general medical ward during the peak inﬂuenza season were tested by RT-PCR for inﬂuenza virus M gene only during the routine clinical testing.
dThe denominator includes those patients for whom their saliva specimens were tested negative for respiratory viruses. This is because these patients may have a low quantity of respiratory virus
present in their saliva specimens but below the detection limit of the assay.
Figure 2 Viral loads in the NPA and the saliva specimens for all patients in the ﬁrst cohort. The number of patients infected with each of the respiratory
viruses is outlined in Table 2. (A) Comparison of viral loads between the NPA and saliva specimens. (B) Comparison of the saliva viral load of inﬂuenza A
and inﬂuenza B in patients with saliva collected before and after oseltamivir treatment. (C) Comparison of the saliva viral loads in patients with or without
pneumonia. Medians, quartiles, and ranges are shown. nasopharyngeal aspirate, NPA.
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DISCUSSION
Novel molecular assays have been developed for the diagnosis of
respiratory virus infections,37–41 which have greatly enhanced the
sensitivity of the detection of respiratory viruses. However, very few
studies have reported an evaluation of specimen types to improve the
detection rate. This study evaluated the use of saliva in addition to
NPA for the diagnosis of respiratory viral infections in two parts. In
the ﬁrst part of this study, saliva had a higher viral load than NPA in
17.0% of the patients who tested positive for respiratory viruses by
DFA or inﬂuenza A virus by RT-PCR in their NPA samples. In the
second part of this study, saliva specimens tested positive in eight
(9.4%) of the 85 patients whose NPA specimens tested negative by
multiplex PCR. Among the 14 patients whose NPA specimens were
unsuitable for DFA or tested negative by DFA but positive by
multiplex PCR, one patient (7.1%) had an additional respiratory virus
detected in her saliva specimen using multiplex PCR. Importantly, a
change in antiviral treatment or isolation precaution could have
occurred in six out of these 9 patients with additional respiratory
viruses detected in their saliva.
In some previous studies, saliva was obtained using a dropper29 or a
special sponge on a stick.28 The advantage of using these devices is that
the amount of saliva is standardized, and the saliva is less likely to be
contaminated by sputum. However, these collection devices are not
usually available in a general medical ward setting. Furthermore, the
collection of saliva with these devices requires help from healthcare
workers. In the present study, we simply asked the patients to
expectorate saliva into the standard sterile sputum containers used
routinely in our hospital. As no special collection device is required,
the use of expectorated saliva can be implemented easily in daily
clinical practice. One possible concern is that the expectorated saliva
may be mixed with sputum, which may contain a higher viral load
than saliva. However, because the aim of using saliva is to increase the
detection rate, this perceived limitation is actually favorable.
In real-life clinical practice, testing both NPA and saliva simulta-
neously is too costly. A more cost-effective approach is to test saliva
only if the NPA result is negative. Hence, in the current study, we
mimic this situation by collecting saliva only when the NPA result is
available. Our previous studies on inﬂuenza viruses showed that
patients usually had higher viral loads in their NPA upon hospital
admission.33,34,42 Therefore, saliva collected later may have a lower
viral load and may result in a lower sensitivity of detection.
Although this study was primarily designed to evaluate the
incremental beneﬁt of testing saliva in addition to NPA, the results
provided some insights into the potential use of testing saliva alone.
Among NPA-positive specimens, the detection rate in saliva was
91.8% (146/159) in the ﬁrst part of the study and 57.1% (8/14) in the
second part of the study. Notably, the detection rate of respiratory
Table 3 Detection of respiratory viruses in nasopharyngeal aspirate and saliva using NxTAG Respiratory Pathogen Panel in the second cohort of
patientsa
Number (%) of patients
All NPA (n=99) NPA with sufﬁcient nasopharyngeal epithelial cells (n=80)
Number of patients with ≥1 respiratory virus detected
NPA or saliva 22 (22.2) 17 (21.3)
NPA 14 (14.1) 12 (15.0)
Saliva 16 (16.2) 12 (15.0)
Concordant
Same respiratory virus detected in both NPA and saliva 6 (6.1) 5 (6.3)
No respiratory viruses detected in NPA or saliva 77 (77.8) 63 (78.8)
Total 83 (83.8) 68 (85.0)
Discordant
Additional respiratory virus detected in saliva 9 (9.1)b 6 (7.5)
Additional respiratory virus detected in NPA 7 (7.1)c 6 (7.5)
Total 16 (16.2) 12 (15.0)
Abbreviation: nasopharyngeal aspirate, NPA.
aRespiratory viruses detected by NxTAG Respiratory Pathogen Panel include inﬂuenza A virus, inﬂuenza B virus, respiratory syncytial viruses A and B, enterovirus/rhinovirus, parainﬂuenza viruses
1-4, human metapneumovirus, adenovirus, coronaviruses HKU1, NL63, 229E and OC43, and human bocavirus.
bFor eight patients, respiratory virus was not detected in the NPA by multiplex PCR. For one patient (patient 4 in Table 5), enterovirus/rhinovirus was detected in both NPA and saliva, but human
metapneumovirus was detected in saliva only.
cFor six patients, respiratory virus was not detected in saliva. For one patient, human metapneumovirus and respiratory syncytial virus A was detected in both NPA and saliva, but coronavirus 229E
was detected in NPA only.
Table 4 Respiratory viruses detected using multiplex PCR panel in
the second cohort of patientsa
Respiratory virus Number of patients
Totalb NPA and saliva NPA only Saliva only
Human metapneumovirus 9 3 3 3
Rhinovirus/enterovirus 4 1 1 2
Inﬂuenza A 5 1 1 3
Inﬂuenza B 2 2 0 0
Respiratory syncytial virus 2 2 0 0
Coronavirus OC43 1 0 0 1
Coronavirus 229E 1 0 1 0
Adenovirus 1 0 1 0
Total 25 9 7 9
Abbreviation: nasopharyngeal aspirate, NPA.
aMultiplex PCR was performed using NxTAG Respiratory Pathogen Panel, which included
inﬂuenza A and B, inﬂuenza A H1, inﬂuenza A H3, respiratory syncytial viruses A and B,
respiratory syncytial virus B, parainﬂuenza viruses 1-4, human bocavirus, human
metapneumovirus, rhinovirus/enterovirus, adenovirus, coronavirus (HKU1, NL63, OC43 and
229E), Chlamydophila pneumoniae and Mycoplasma pneumoniae. The atypical bacterial
pathogens C. pneumoniae and M. pneumoniae were excluded from the analysis.
bTwo patients had more than one respiratory virus detected (one patient with human
metapneumovirus and enterovirus/rhinovirus; 1 patient with human metapneumovirus,
respiratory syncytial virus A and coronavirus 229E).
Detection of respiratory viruses in saliva
KKW To et al
5
Emerging Microbes & Infections
viruses by multiplex PCR in the second part of the study was slightly
higher in saliva (16.2%) than in NPA (14.1%). Kim et al also showed
that multiplex PCR of saliva and NPS specimens had similar detection
rates.18 Therefore, the use of saliva alone may not be inferior to the use
of NPA if only a single type of specimen is tested. Testing saliva over
NPA has many advantages. First, collecting saliva rather than NPA
avoids patient discomfort.43 Second, the collection of saliva is suitable
for patients for whom the collection of nasopharyngeal specimens is
contraindicated, such as patients with severe bleeding tendency. Third,
patients can provide saliva specimens after simple instruction, whereas
the collection of nasopharyngeal specimens must be performed by
healthcare personnel. This approach would reduce the delay in
specimen collection. Finally, the collection of saliva does not require
any special infection control precautions and can be performed in any
clinical setting with standard precautions. By contrast, the procedures
for the collection of nasopharyngeal specimens are potentially aerosol-
generating and therefore pose signiﬁcant risks to healthcare workers
and other patients. Some health authorities have recommended that
nasopharyngeal specimens should be collected in a negative pressure
isolation room for patients with suspected MERS coronavirus or novel
inﬂuenza viruses.44
Sputum is also a non-invasive specimen that has been used for the
detection of respiratory viruses, especially in patients with
pneumonia.17,19,22 However, many patients with respiratory virus
infection do not have sputum production or cannot expectorate good
quality sputum. By contrast, saliva specimens can be obtained much
more easily than sputum specimens.
DFA is routinely used in our clinical setting for the diagnosis of
respiratory virus infections. The advantages of DFA include a relatively
low cost, rapid results and simultaneous detection of multiple viral
pathogens. However, the sensitivity of DFA is low compared with
molecular assays. During the 2009 inﬂuenza pandemic, the sensitivity
of DFA ranged from 39% to 93%.5 DFA also has a low sensitivity for
inﬂuenza A H7N9 virus infection.40 Another disadvantage of DFA is
that it is not suitable for saliva specimens, because DFA can only detect
viral antigens that are present inside infected cells, which are not
present in the saliva. Therefore, to avoid bias between different tests,
we used a multiplex PCR panel to test both the NPA and the saliva
specimens. Although the multiplex PCR panel used in the second
cohort (the NxTAG Respiratory Pathogen Panel) is more sensitive
than DFA, it has lower sensitivity than real-time RT-PCR assays. The
sensitivity of the NxTAG Respiratory Pathogen Panel ranged from
71.4% to 100% compared with real-time PCR or RT-PCR.45 There-
fore, some patients with respiratory virus infection may be missed
even when NPA and saliva specimens are tested with this multiplex
PCR panel.
This study has several limitations. First, our saliva collection method
is not suitable for patients who cannot expectorate saliva, such as
patients who are unconscious. For these patients, suction aspiration of
saliva is required. Second, in the ﬁrst cohort, we only evaluated viruses
included in the routine DFA or inﬂuenza A virus RT-PCR. Other
important respiratory viruses, such as rhinoviruses and coronaviruses,
need to be further evaluated. Third, the number of specimens of each
virus species is too small to compare the differences in sensitivity for
speciﬁc virus species.
Although the viral load in the saliva is lower than the viral load in
the NPA for most patients, we have shown that testing both
expectorated saliva and NPA can signiﬁcantly improve the detection
of respiratory viruses compared with testing of NPA alone. Saliva
should be obtained from patients with a suspected respiratory virus
infection but a negative test for respiratory viruses. Furthermore, saliva
should be evaluated as the specimen type in a diagnostic testing for
Table 5 Nine patients with additional respiratory viruses detected only in their saliva for the second cohort of patients
Case
Number
Sex/
age in
years
Underlying medical conditions Presenting symptom; ﬁnal
diagnosis
Respiratory
virus detected
in NPAa
Additional virus
detected in
salivaa
Potential changes in antiviral
treatment or infection control
practice
1 M/56 Nasopharyngeal carcinoma Productive cough, dyspnea;
pneumonia
Negativeb Inﬂuenza A H1 Neuraminidase inhibitor
2 F/78 Gout Fever, dyspnea; lower
respiratory tract infection
Negativeb Inﬂuenza A H3 Neuraminidase inhibitor
3 M/81 DM, Ca prostate Productive cough; upper
respiratory tract infection
Negativec Inﬂuenza A H3 Neuraminidase inhibitor
4 F/81 Hypertension, hyperlipidemia, IFG Rhinorrhea, cough,
dyspnea, wheeze; pneumonia
EV/RVb hMPV Contact precaution
5 M/72 DM, hypertension Fever, rhinorrhea, dry cough;
pneumonia
Negativeb hMPV Contact precaution
6 M/55 Schizophrenia, gout, CVA Fever, productive cough;
pneumonia
Negativec hMPV Contact precaution
7 M/63 Asthma, Churg-Strauss syndrome Productive cough, dyspnea;
asthmatic attack
Negativeb EV/RV Nil
8 F/63 Stage IV lymphoma, hypertension, asthma Fever, productive cough,
chills; upper respiratory tract
infection
Negativeb EV/RV Nil
9 M/79 Ischemic heart disease, diabetic nephropathy, Ca
prostate with bone metastasis, pemphigoid,
bronchiectasis
Fever and dizziness; CAPD
peritonitis
Negativec Coronavirus
OC43
Nil
Abbreviations: carcinoma, Ca; continuous ambulatory peritoneal dialysis, CAPD; cerebrovascular accident, CVA; diabetes mellitus, DM; enterovirus/rhinovirus, EV/RV; human metapneumovirus, hMPV;
impaired fasting glucose, IFG.
aRespiratory virus detection was performed using NxTAG Respiratory Pathogen Panel.
bSufﬁcient nasopharyngeal columnar epithelial cells detected during DFA.
cInsufﬁcient nasopharyngeal columnar epithelial cells detected during DFA.
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novel respiratory viruses. This approach will ultimately lead to
improvement in the management of patients and the prevention of
community or nosocomial spread of infections.
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